UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 2, 2020
Pacific Biosciences of California, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | 001-34899 | | 16-1590339 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
1305 O’Brien Drive
Menlo Park, California 94025
(Address of principal executive offices) (Zip Code)
(650) 521-8000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, par value $0.001 per share | | PACB | | The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| |
ITEM 5.02. | DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS |
In conjunction with its annual review of the leadership structure of the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”) and in keeping with good governance practices, the Board has decided to separate the Chair and Chief Executive Officer positions. On March 2, 2020, the Board appointed Christian O. Henry as Chairman of the Board, effective immediately. Michael Hunkapiller will continue to serve as a member of the Board and the President and Chief Executive of the Company.
In connection with Mr. Henry’s appointment as Chairman of the Board, Mr. Henry will receive an additional annual retainer of $35,000 as well as a stock option to purchase 35,000 shares of the Company’s common stock.
In light of the appointment of an independent Chairman, the Board eliminated the position of Lead Independent Director. As a result, William Ericson will no longer serve as the Company’s Lead Independent Director, but will continue to serve as a member of the Board, Chair of the Compensation Committee of the Board and member of the Nominating and Corporate Governance Committee of the Board.
Item 9.01.FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit No. Description
99.1Press Release dated March 5, 2020 titled “Christian Henry Appointed Chairman of Pacific Biosciences’ Board of Directors”
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
Pacific Biosciences of California, Inc. |
| |
By: | | /s/ Susan K. Barnes |
| | Susan K. Barnes Executive Vice President, Chief Financial Officer & Principal Accounting Officer |
Date: March 5, 2020
